Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist

Neuropharmacology

Volumn 116, Issue , 2017, Pages 371-386

  Ardestani, Pooneh Memar ^a   Evans, Andrew K ^a   Yi, Bitna ^a   Nguyen, Tiffany ^a   Coutellier, Laurence ^a,b   Shamloo, Mehrdad ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

5XFAD; Alzheimer's disease; Amyloid beta; Beta 1 adrenergic receptor; Neuroinflammation; Xamoterol

Indexed keywords

AMYLOID BETA PROTEIN; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ARRESTIN; CALCIUM BINDING PROTEIN; CD14 ANTIGEN; CD74 ANTIGEN; CYCLIC AMP; IONIZED CALCIUM BINDING ADAPTER MOLECULE 1; MESSENGER RNA; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; XAMOTEROL; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

5XFAD MOUSE; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTOSIS; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BRAIN LEVEL; DRUG SELECTIVITY; ELEVATED PLUS MAZE TEST; FEAR CONDITIONING TEST; GENE EXPRESSION; GLIOSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LOW DRUG DOSE; MICROGLIA; MORRIS WATER MAZE TEST; MOUSE; MOUSE MODEL; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OPEN FIELD TEST; RAT; Y-MAZE TEST; ANIMAL; BRAIN; CHO CELL LINE; CRICETULUS; DISEASE MODEL; DRUG EFFECT; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADRENERGIC BETA-1 RECEPTOR AGONISTS; ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-ARRESTINS; BRAIN; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; CYCLIC AMP; DISEASE MODELS, ANIMAL; HEK293 CELLS; HUMANS; INFLAMMATION; MICE, TRANSGENIC; MICROGLIA; NEUROPROTECTIVE AGENTS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-1; RNA, MESSENGER; XAMOTEROL;

EID: 85009927030     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2017.01.010     Document Type: Article

References (77)

1. Allen, J.A., Yost, J.M., Setola, V., Chen, X., Sassano, M.F., Chen, M., et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 18488–18493.
2. Baker, J.G., The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br. J. Pharmacol. 144 (2005), 317–322.
3. Blanchard, V., Moussaoui, S., Czech, C., Touchet, N., Bonici, B., Planche, M., et al. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp. Neurol. 184 (2003), 247–263.
4. Bondareff, W., Mountjoy, C.Q., Roth, M., Rossor, M.N., Iversen, L.L., Reynolds, G.P., et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1 (1987), 256–262.
5. Braak, H., Thal, D.R., Ghebremedhin, E., Del, T.K., Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70 (2011), 960–969.
6. Branca, C., Wisely, E.V., Hartman, L.K., Caccamo, A., Oddo, S., Administration of a selective beta2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiol. Aging 35 (2014), 2726–2735.
7. Bullido, M.J., Ramos, M.C., Ruiz-Gomez, A., Tutor, A.S., Sastre, I., Frank, A., et al. Polymorphism in genes involved in adrenergic signaling associated with Alzheimer's. Neurobiol. Aging 25 (2004), 853–859.
8. Bylund, D.B., Eikenberg, D.C., Hieble, J.P., Langer, S.Z., Lefkowitz, R.J., Minneman, K.P., et al. International union of pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46 (1994), 121–136.
9. Corcoran, K.A., Frick, B.J., Radulovic, J., Kay, L.M., Analysis of coherent activity between retrosplenial cortex, hippocampus, thalamus, and anterior cingulate cortex during retrieval of recent and remote context fear memory. Neurobiol. Learn Mem. 127 (2016), 93–101.
10. Coutellier, L., Ardestani, P.M., Shamloo, M., beta1-adrenergic receptor activation enhances memory in Alzheimer's disease model. Ann. Clin. Transl. Neurol. 1 (2014), 348–360.
11. Cunningham, C., Campion, S., Lunnon, K., Murray, C.L., Woods, J.F., Deacon, R.M., et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol. Psychiatry 65 (2009), 304–312.
12. Day, J.S., O'Neill, E., Cawley, C., Aretz, N.K., Kilroy, D., Gibney, S.M., et al. Noradrenaline acting on astrocytic beta(2)-adrenoceptors induces neurite outgrowth in primary cortical neurons. Neuropharmacology 77 (2014), 234–248.
13. Devi, L., Alldred, M.J., Ginsberg, S.D., Ohno, M., Sex- and brain region-specific acceleration of beta-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Mol. Brain, 3, 2010, 34.
14. Dhawan, G., Floden, A.M., Combs, C.K., Amyloid-beta oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiol. Aging 33 (2012), 2247–2261.
15. Faizi, M., Bader, P.L., Saw, N., Nguyen, T.V., Beraki, S., Wyss-Coray, T., et al. Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav. 2 (2012), 142–154.
16. Faizi, M., Bader, P.L., Tun, C., Encarnacion, A., Kleschevnikov, A., Belichenko, P., et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol. Dis. 43 (2011), 397–413.
17. Freedman, N.J., Lefkowitz, R.J., Desensitization of G protein-coupled receptors. Recent Prog. Horm. Res. 51 (1996), 319–351.
18. Fu, R., Shen, Q., Xu, P., Luo, J.J., Tang, Y., Phagocytosis of microglia in the central nervous system diseases. Mol. Neurobiol. 49 (2014), 1422–1434.
19. Fujita, H., Tanaka, J., Maeda, N., Sakanaka, M., Adrenergic agonists suppress the proliferation of microglia through beta 2-adrenergic receptor. Neurosci. Lett. 242 (1998), 37–40.
20. German, D.C., Manaye, K.F., White, C.L. III, Woodward, D.J., McIntire, D.D., Smith, W.K., et al. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32 (1992), 667–676.
21. Girard, S.D., Jacquet, M., Baranger, K., Migliorati, M., Escoffier, G., Bernard, A., et al. Onset of hippocampus-dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer's disease. Hippocampus 24 (2014), 762–772.
22. Heneka, M.T., Galea, E., Gavriluyk, V., Dumitrescu-Ozimek, L., Daeschner, J., O'Banion, M.K., et al. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22 (2002), 2434–2442.
23. Heneka, M.T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 6058–6063.
24. Heneka, M.T., Ramanathan, M., Jacobs, A.H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26 (2006), 1343–1354.
25. Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T.A., Wirths, O., Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33 (2012), 196.e29–196.e40.
26. Kaczorowski, C.C., Sametsky, E., Shah, S., Vassar, R., Disterhoft, J.F., Mechanisms underlying basal and learning-related intrinsic excitability in a mouse model of Alzheimer's disease. Neurobiol. Aging 32 (2011), 1452–1465.
27. Kalaria, R.N., Andorn, A.C., Tabaton, M., Whitehouse, P.J., Harik, S.I., Unnerstall, J.R., Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J. Neurochem. 53 (1989), 1772–1781.
28. Kalinin, S., Gavrilyuk, V., Polak, P.E., Vasser, R., Zhao, J., Heneka, M.T., et al. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 28 (2007), 1206–1214.
29. Kalinin, S., Polak, P.E., Lin, S.X., Sakharkar, A.J., Pandey, S.C., Feinstein, D.L., The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol. Aging 33 (2012), 1651–1663.
30. Kan, M.J., Lee, J.E., Wilson, J.G., Everhart, A.L., Brown, C.M., Hoofnagle, A.N., et al. Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease. J. Neurosci. 35 (2015), 5969–5982.
31. Kimura, R., Ohno, M., Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 33 (2009), 229–235.
32. Koronyo-Hamaoui, M., Ko, M.K., Koronyo, Y., Azoulay, D., Seksenyan, A., Kunis, G., et al. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J. Neurochem. 111 (2009), 1409–1424.
33. Lambert, J.C., Grenier-Boley, B., Chouraki, V., Heath, S., Zelenika, D., Fievet, N., et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J. Alzheimers Dis. 20 (2010), 1107–1118.
34. Macbeth, A.H., Edds, J.S., Young, W.S. III, Housing conditions and stimulus females: a robust social discrimination task for studying male rodent social recognition. Nat. Protoc. 4 (2009), 1574–1581.
35. Madrigal, J.L., Feinstein, D.L., Dello, R.C., Norepinephrine protects cortical neurons against microglial-induced cell death. J. Neurosci. Res. 81 (2005), 390–396.
36. Madrigal, J.L., Leza, J.C., Polak, P., Kalinin, S., Feinstein, D.L., Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J. Neurosci. 29 (2009), 263–267.
37. Maillet, E.L., Milon, N., Heghinian, M.D., Fishback, J., Schurer, S.C., Garamszegi, N., et al. Noribogaine is a G-protein biased kappa-opioid receptor agonist. Neuropharmacology 99 (2015), 675–688.
38. Markus, T., Hansson, S.R., Cronberg, T., Cilio, C., Wieloch, T., Ley, D., beta-Adrenoceptor activation depresses brain inflammation and is neuroprotective in lipopolysaccharide-induced sensitization to oxygen-glucose deprivation in organotypic hippocampal slices. J. Neuroinflammation, 7, 2010, 94.
39. Marsh, S.E., Abud, E.M., Lakatos, A., Karimzadeh, A., Yeung, S.T., Davtyan, H., et al. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E1316–E1325.
40. Mather, M., Harley, C.W., The locus coeruleus: Essential for maintaining cognitive function and the aging brain. Trends Cogn. Sci. 20 (2016), 214–226.
41. Matthews, K.L., Chen, C.P., Esiri, M.M., Keene, J., Minger, S.L., Francis, P.T., Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry 51 (2002), 407–416.
42. Modi, K.K., Jana, A., Ghosh, S., Watson, R., Pahan, K., A physically-modified saline suppresses neuronal apoptosis, attenuates tau phosphorylation and protects memory in an animal model of Alzheimer's disease. PLoS One, 9, 2014, e103606.
43. Mori, K., Ozaki, E., Zhang, B., Yang, L., Yokoyama, A., Takeda, I., et al. Effects of norepinephrine on rat cultured microglial cells that express alpha1, alpha2, beta1 and beta2 adrenergic receptors. Neuropharmacology 43 (2002), 1026–1034.
44. Murchison, C.F., Schutsky, K., Jin, S.H., Thomas, S.A., Norepinephrine and ss(1)-adrenergic signaling facilitate activation of hippocampal CA1 pyramidal neurons during contextual memory retrieval. Neuroscience 181 (2011), 109–116.
45. Murchison, C.F., Zhang, X.Y., Zhang, W.P., Ouyang, M., Lee, A., Thomas, S.A., A distinct role for norepinephrine in memory retrieval. Cell 117 (2004), 131–143.
46. Nguyen, T.V., Shen, L., Vander, G.L., Quach, L.N., Belichenko, N.P., Saw, N., et al. Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AbetaPPL/S transgenic mice. J. Alzheimers Dis. 42:2 (2014), 459–483.
47. Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26 (2006), 10129–10140.
48. Ohno, M., Failures to reconsolidate memory in a mouse model of Alzheimer's disease. Neurobiol. Learn Mem. 92 (2009), 455–459.
49. Paxinos, G., Franklin, K.B.J., The Mouse Brain in Stereotaxic Coordinates. 2001, Academic Press, San Diego.
50. Pierce, K.L., Lefkowitz, R.J., Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2 (2001), 727–733.
51. Qian, L., Wu, H.M., Chen, S.H., Zhang, D., Ali, S.F., Peterson, L., et al. beta2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway. J. Immunol. 186 (2011), 4443–4454.
52. Rajagopal, S., Rajagopal, K., Lefkowitz, R.J., Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9 (2010), 373–386.
53. Rezai-Zadeh, K., Gate, D., Gowing, G., Town, T., How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr. Alzheimer Res. 8 (2011), 156–163.
54. Rosenberg, P.B., Mielke, M.M., Tschanz, J., Cook, L., Corcoran, C., Hayden, K.M., et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am. J. Geriatr. Psychiatry 16 (2008), 883–892.
55. Ross, J.A., McGonigle, P., Van Bockstaele, E.J., Locus Coeruleus, norepinephrine and Abeta peptides in Alzheimer's disease. Neurobiol. Stress 2 (2015), 73–84.
56. Ryan, K.J., Griffin, E., Yssel, J.D., Ryan, K.M., McNamee, E.N., Harkin, A., et al. Stimulation of central beta2-adrenoceptors suppresses NFkappaB activity in rat brain: a role for IkappaB. Neurochem. Int. 63 (2013), 368–378.
57. Samuels, E.R., Szabadi, E., Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation. Curr. Neuropharmacol. 6 (2008), 235–253.
58. Saul, A., Sprenger, F., Bayer, T.A., Wirths, O., Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 34 (2013), 2564–2573.
59. Savage, J.C., Jay, T., Goduni, E., Quigley, C., Mariani, M.M., Malm, T., et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. J. Neurosci. 35 (2015), 6532–6543.
60. Saxe, M.D., Battaglia, F., Wang, J.W., Malleret, G., David, D.J., Monckton, J.E., et al. Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 17501–17506.
61. Schmittgen, T.D., Livak, K.J., Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3 (2008), 1101–1108.
62. Schneider, F., Baldauf, K., Wetzel, W., Reymann, K.G., Behavioral and EEG changes in male 5xFAD mice. Physiol. Behav. 135 (2014), 25–33.
63. Schneider, F., Baldauf, K., Wetzel, W., Reymann, K.G., Effects of methylphenidate on the behavior of male 5xFAD mice. Pharmacol. Biochem. Behav. 128 (2015), 68–77.
64. Schutsky, K., Ouyang, M., Castelino, C.B., Zhang, L., Thomas, S.A., Stress and glucocorticoids impair memory retrieval via beta2-adrenergic, Gi/o-coupled suppression of cAMP signaling. J. Neurosci. 31 (2011), 14172–14181.
65. Schutsky, K., Ouyang, M., Thomas, S.A., Xamoterol impairs hippocampus-dependent emotional memory retrieval via Gi/o-coupled beta2-adrenergic signaling. Learn Mem. 18 (2011), 598–604.
66. Schwartz, M., Shechter, R., Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol. 6 (2010), 405–410.
67. Shimohama, S., Taniguchi, T., Fujiwara, M., Kameyama, M., Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia. J. Neurochem. 48 (1987), 1215–1221.
68. Sil, S., Ghosh, T., Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's Disease. J. Neuroimmunol. 291 (2016), 115–124.
69. Singhal, G., Jaehne, E.J., Corrigan, F., Toben, C., Baune, B.T., Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front. Neurosci., 8, 2014, 315.
70. Suryono, Kido J., Hayashi, N., Kataoka, M., Shinohara, Y., Nagata, T., Norepinephrine stimulates calprotectin expression in human monocytic cells. J. Periodontal Res. 41 (2006), 159–164.
71. Tanaka, K.F., Kashima, H., Suzuki, H., Ono, K., Sawada, M., Existence of functional beta1- and beta2-adrenergic receptors on microglia. J. Neurosci. Res. 70 (2002), 232–237.
72. Tejani-Butt, S.M., Yang, J., Zaffar, H., Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease. Brain Res. 631 (1993), 147–150.
73. Thomas, S.A., Neuromodulatory signaling in hippocampus-dependent memory retrieval. Hippocampus 25 (2015), 415–431.
74. Todd, T.P., Bucci, D.J., Retrosplenial cortex and long-Term memory: molecules to behavior. Neural Plast., 2015, 2015, 414173.
75. Violin, J.D., Lefkowitz, R.J., Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28 (2007), 416–422.
76. Yang, J.H., Lee, E.O., Kim, S.E., Suh, Y.H., Chong, Y.H., Norepinephrine differentially modulates the innate inflammatory response provoked by amyloid-beta peptide via action at beta-adrenoceptors and activation of cAMP/PKA pathway in human THP-1 macrophages. Exp. Neurol. 236 (2012), 199–206.
77. Zhang, J., Ferguson, S.S., Barak, L.S., Aber, M.J., Giros, B., Lefkowitz, R.J., et al. Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Recept. Channels 5 (1997), 193–199.